Vistagen Therapeutics Inc.
VTGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.47M
Close$
$0.72
154.6% upside
Current Fair Value
154.6% upsideUndervalued by 154.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.47 Million |
|---|---|
| Enterprise Value | $-3,504,091.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.39 |
| Outstanding Shares | 42,980,174 |
Return
| Return on Equity | -276.21% |
|---|---|
| Return on Assets | -189.22% |
| Return on Invested Capital | -283.29% |
Valuation & Multiples
| P/E Ratio | -0.17 |
|---|---|
| PEG | 1.21 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.4 |
| Enterprise Value to EBIT | 0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.29 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0716▲ 0.25% |
|---|---|
| Total Calls | 1,172,347▲ 126.85% |
| Total Puts | 83,900▲ 135.01% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.40%▼ 9.78% |
|---|---|
| Total Invested | $2.54M▼ 68.71% |
| Investors Holding | 58▼ 3.00% |
ESG Score
No data
About VistaGen Therapeutics Inc
21 employeesVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...